Invesco Ltd. Sells 89,660 Shares of Haleon plc (NYSE:HLN)

Invesco Ltd. decreased its position in Haleon plc (NYSE:HLN - Free Report) by 5.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,622,516 shares of the company's stock after selling 89,660 shares during the quarter. Invesco Ltd.'s holdings in Haleon were worth $15,479,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Procyon Advisors LLC raised its holdings in Haleon by 41.3% in the 4th quarter. Procyon Advisors LLC now owns 230,240 shares of the company's stock worth $2,196,000 after acquiring an additional 67,329 shares during the period. Jane Street Group LLC increased its stake in shares of Haleon by 1,689.4% in the third quarter. Jane Street Group LLC now owns 264,977 shares of the company's stock worth $2,803,000 after purchasing an additional 250,169 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Haleon by 29.8% in the fourth quarter. Bank of New York Mellon Corp now owns 2,071,017 shares of the company's stock worth $19,758,000 after purchasing an additional 475,934 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Haleon by 25.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company's stock worth $53,791,000 after purchasing an additional 1,026,939 shares during the last quarter. Finally, SeaCrest Wealth Management LLC bought a new stake in Haleon during the 4th quarter valued at approximately $102,000. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Haleon Stock Performance

HLN traded up $0.03 during trading on Friday, reaching $10.22. 7,922,972 shares of the company's stock were exchanged, compared to its average volume of 7,291,865. Haleon plc has a fifty-two week low of $8.12 and a fifty-two week high of $10.80. The company has a market capitalization of $46.13 billion, a P/E ratio of 29.93, a PEG ratio of 2.82 and a beta of 0.24. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The business has a 50 day moving average price of $10.13 and a 200 day moving average price of $9.81.

Haleon (NYSE:HLN - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. The business had revenue of $3.54 billion for the quarter, compared to analysts' expectations of $3.38 billion. Haleon had a net margin of 10.85% and a return on equity of 14.76%. As a group, analysts predict that Haleon plc will post 0.43 earnings per share for the current fiscal year.

Haleon Increases Dividend

The business also recently announced a -- dividend, which will be paid on Thursday, June 5th. Stockholders of record on Friday, April 25th will be issued a $0.1166 dividend. The ex-dividend date of this dividend is Friday, April 25th. This is a boost from Haleon's previous -- dividend of $0.05. This represents a dividend yield of 1.6%. Haleon's dividend payout ratio is presently 58.97%.

Wall Street Analysts Forecast Growth

HLN has been the subject of a number of research analyst reports. Morgan Stanley lowered Haleon from an "overweight" rating to an "equal weight" rating in a report on Friday, January 10th. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Haleon in a research note on Monday, March 3rd. HSBC restated a "hold" rating on shares of Haleon in a research report on Wednesday, March 5th. Sanford C. Bernstein lowered shares of Haleon from an "outperform" rating to a "market perform" rating in a research report on Wednesday, January 8th. Finally, Hsbc Global Res downgraded Haleon from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, March 5th. Six research analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Haleon presently has an average rating of "Hold" and an average price target of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.